公开(公告)号：US20240360114A1

公开(公告)日：2024-10-31

申请号：US18293357

申请日：2022-08-09

申请人： SIRONAX LTD.

发明人： Jianguang HAN ,  Weijie HOU ,  Zhiyuan ZHANG ,  Yanping XU ,  Yimin JIANG ,  Xingyu XU

IPC分类号： C07D413/04 ,  A61K31/4427 ,  A61K31/47 ,  A61K31/496 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/553 ,  C07C211/48 ,  C07D213/74 ,  C07D215/10 ,  C07D215/16 ,  C07D241/04 ,  C07D265/30 ,  C07D401/04 ,  C07D413/14 ,  C07D487/08 ,  C07D491/048 ,  C07D491/107

CPC分类号： C07D413/04 ,  A61K31/4427 ,  A61K31/47 ,  A61K31/496 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/553 ,  C07C211/48 ,  C07D213/74 ,  C07D215/10 ,  C07D215/16 ,  C07D241/04 ,  C07D265/30 ,  C07D401/04 ,  C07D413/14 ,  C07D487/08 ,  C07D491/048 ,  C07D491/107

摘要： This disclosure provides compounds of Formula I, compositions comprising the same, and methods of using the same, including use in treating various diseases and conditions, e.g., those involving ferroptosis.

公开(公告)号：US12133459B2

公开(公告)日：2024-10-29

申请号：US17282678

申请日：2020-01-13

申请人： LG CHEM, LTD.

发明人： Sang Duk Suh ,  Dong Hoon Lee ,  Boon Jae Jang ,  Min Woo Jung ,  Jungha Lee ,  Su Jin Han ,  Seulchan Park ,  Sunghyun Hwang

IPC分类号： H10K85/60 ,  C07D491/048 ,  C07D495/04 ,  H10K50/11

CPC分类号： H10K85/654 ,  C07D491/048 ,  C07D495/04 ,  H10K85/657 ,  H10K85/6572 ,  H10K85/6574 ,  H10K50/11

摘要： A heterocyclic compound represented by Chemical Formula 1 and an organic light emitting device comprising the same, and the heterocyclic compound used as a material of an organic material layer of the organic light emitting device and providing improved properties of efficiency, driving voltage and lifetime characteristics of the organic light emitting device.

公开(公告)号：US20240343709A1

公开(公告)日：2024-10-17

申请号：US18746835

申请日：2024-06-18

申请人： KayoThera Inc. ,  The Trustees of Princeton University

发明人： Mark ESPOSITO ,  John PROUDFOOT ,  Yibin KANG ,  John PIWINSKI

IPC分类号： C07D401/12 ,  A61P35/00 ,  C07D215/50 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D491/048 ,  C07D498/04 ,  C07D513/04

CPC分类号： C07D401/12 ,  A61P35/00 ,  C07D215/50 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D491/048 ,  C07D498/04 ,  C07D513/04

摘要： Provided herein are novel heterocyclic compounds, for example, compounds of Formula (IV-C). Also provided herein are pharmaceutical compositions comprising the compounds and methods of using the same, for example, in inhibiting aldehyde dehydrogenases, retinoid pathway activation, and/or for treating various cancers, cancer metastasis, type 2 diabetes, pulmonary arterial hypertension (PAH) or neointimal hyperplasia (NIH) or as a male contraceptive.

公开(公告)号：US20240336608A1

公开(公告)日：2024-10-10

申请号：US18617907

申请日：2024-03-27

申请人： Merck Sharp & Dohme LLC

发明人： David A. Candito ,  Anthony Donofrio ,  Ronald Dale Ferguson, II ,  George Madalin Giambasu ,  Anmol Gulati ,  Andrew M. Haidle ,  Brett A. Hopkins ,  William P. Kaplan ,  Ping Liu ,  Michaelyn C. Lux ,  Xiao Mei Zheng ,  Ryan D. Otte ,  Alexander Pasternak ,  Elsie C. Yu

IPC分类号： C07D417/14 ,  A61K31/422 ,  A61K31/433 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/542 ,  A61K39/395 ,  C07D401/14 ,  C07D403/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07D491/048 ,  C07D495/04 ,  C07D513/04

CPC分类号： C07D417/14 ,  A61K31/422 ,  A61K31/433 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/542 ,  A61K39/3955 ,  C07D401/14 ,  C07D403/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07D491/048 ,  C07D495/04 ,  C07D513/04

摘要： Described herein are compounds of Formula I




or a pharmaceutically acceptable salt thereof, wherein R1, R2, A, and B are as defined herein. The compounds of Formula I act as IL4I1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for IL4I1-related diseases.

公开(公告)号：US12110288B2

公开(公告)日：2024-10-08

申请号：US17112906

申请日：2020-12-04

申请人： Omeros Corporation

发明人： Neil S. Cutshall ,  Jennifer Lynn Gage ,  Do Yeon Kwon ,  Thomas L Little ,  Markus Metz ,  Peter Kurt Nollert von Specht ,  Jennifer Tsoung ,  Jeremiah H. Nguyen ,  Melinda Davis ,  Robert Huerta Lemus ,  Santosh Kumar Keshipeddy ,  Sara Rebecca Goldstein

IPC分类号： C07D471/04 ,  A61K31/495 ,  A61K31/497 ,  C07D239/545 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  C07D491/048 ,  C07D495/04 ,  C07D519/00

CPC分类号： C07D471/04 ,  C07D239/545 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  C07D491/048 ,  C07D495/04 ,  C07D519/00

摘要： The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.

公开(公告)号：US20240317721A1

公开(公告)日：2024-09-26

申请号：US18571588

申请日：2022-06-22

申请人： NOVARTIS AG

发明人： Claudio BOMIO-CONFAGLIA ,  Saskia Maria BRACHMANN ,  Simona COTESTA ,  Marc GERSPACHER ,  Catherine LEBLANC ,  Fabio LIMA ,  Edwige Liliane Jeanne LORTHIOIS ,  Rainer MACHAUER ,  Robert MAH ,  Sophie RACINE ,  Pascal RIGOLLIER ,  Stefan STUTZ ,  Andrea VAUPEL ,  Nicolas WARIN ,  Rainer WILCKEN ,  Frédéric ZECRI

IPC分类号： C07D403/14 ,  A61K31/416 ,  A61K31/4162 ,  A61K31/437 ,  A61K31/438 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/499 ,  A61K31/4995 ,  A61K31/501 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/547 ,  A61K31/55 ,  A61K31/551 ,  A61K31/553 ,  A61K31/675 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08 ,  C07D491/048 ,  C07D491/107 ,  C07D495/10 ,  C07D498/04 ,  C07D498/08 ,  C07D498/10 ,  C07D513/08 ,  C07F9/6584

CPC分类号： C07D403/14 ,  A61K31/416 ,  A61K31/4162 ,  A61K31/437 ,  A61K31/438 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/499 ,  A61K31/4995 ,  A61K31/501 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/547 ,  A61K31/55 ,  A61K31/551 ,  A61K31/553 ,  A61K31/675 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08 ,  C07D491/048 ,  C07D491/107 ,  C07D495/10 ,  C07D498/04 ,  C07D498/08 ,  C07D498/10 ,  C07D513/08 ,  C07F9/6584

摘要： The present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, and the therapeutic uses of said compound. The present invention further provides a pharmaceutical composition comprising said compound.

公开(公告)号：US20240300970A1

公开(公告)日：2024-09-12

申请号：US18020721

申请日：2022-03-31

申请人： BOE Technology Group Co., Ltd.

发明人： Lei Chen ,  Xueqin Chen ,  Bingyan Liang ,  Dongxu Zhang

IPC分类号： C07D493/04 ,  C07D403/14 ,  C07D491/048 ,  C07D495/04 ,  C07D519/00 ,  H10K50/84

CPC分类号： C07D493/04 ,  C07D403/14 ,  C07D491/048 ,  C07D495/04 ,  C07D519/00 ,  H10K50/84

摘要： The present application provides a light-emitting device and a display device, which relates to the field of display technology, including: a substrate; a first electrode and a second electrode located on the substrate: a light-emitting layer located between the first electrode and the second electrode; and a capping layer located on a side of the second electrode away from the light-emitting layer, wherein the capping layer includes a compound of aromatic amines, and a structure of the compound of aromatic amines includes one of following two structures 1:




and the capping layer made of the compound of aromatic amines has a high refractive index and high stability, such that when the light-emitting device is used, the light-outlet efficiency of the device may be improved, and the service life of the device may be prolonged.

公开(公告)号：US20240294542A1

公开(公告)日：2024-09-05

申请号：US18566865

申请日：2022-06-02

申请人： TransThera Sciences (Nanjing), Inc.

发明人： Lin Li ,  Frank Wu

IPC分类号： C07D495/04 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/5377 ,  C07D237/34 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04 ,  C07D491/048 ,  C07D491/18

CPC分类号： C07D495/04 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/5377 ,  C07D237/34 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04 ,  C07D491/048 ,  C07D491/18

摘要： The present invention belongs to the technical field of medicines, relates to an NLRP3 inflammasome inhibitor and use thereof, and particularly relates to a compound of general formula (I), or a pharmaceutically acceptable salt, a stereoisomer or a tautomer thereof, wherein each group is defined in the specification. Researches show that the compound of general formula (I), or pharmaceutically acceptable salt, the stereoisomer or the tautomer thereof has relatively high biological activity on NLRP3 inflammasomes and has an important clinical development value for the treatment of NLRP3-associated diseases.

公开(公告)号：US20240293412A1

公开(公告)日：2024-09-05

申请号：US18553909

申请日：2022-04-07

申请人： The Board of Trustees of the University of Illinois ,  ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA

发明人： Gregory R THATCHER ,  Rui XIONG ,  Kiira RATIA ,  Yangfeng LI ,  Zhengnan SHEN

IPC分类号： A61K31/519 ,  A61K31/55 ,  C07D487/04 ,  C07D491/048 ,  C07D495/04 ,  C07D519/00

CPC分类号： A61K31/519 ,  A61K31/55 ,  C07D487/04 ,  C07D491/048 ,  C07D495/04 ,  C07D519/00

摘要： In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to compounds and methods for activating NAMPT in a subject. The compounds described herein are useful in treating a neurological disorder, disease, or condition. In another aspect, compounds described herein are useful in treating metabolic disorders and diabetes. Formula (I)

公开(公告)号：US12077546B2

公开(公告)日：2024-09-03

申请号：US18506804

申请日：2023-11-10

申请人： Sumitomo Pharma Co., Ltd.

发明人： Satoshi Adachi ,  Hidefumi Yoshinaga ,  Hajime Shibata ,  Yusuke Shioda ,  Riko Nagahama

IPC分类号： C07D471/04 ,  A61P25/00 ,  C07D213/65 ,  C07D215/12 ,  C07D221/04 ,  C07D401/06 ,  C07D491/048 ,  C07D495/04

CPC分类号： C07D491/048 ,  A61P25/00 ,  C07D213/65 ,  C07D215/12 ,  C07D221/04 ,  C07D401/06 ,  C07D471/04 ,  C07D495/04

摘要： The present disclosure provides bicyclic pyridine derivatives.
A compound represented by formula I:






or a pharmaceutically acceptable salt thereof,
wherein
X is a oxygen atom, sulfur atom, NR, or CR′R″, n is 0 or 1, R1, R2a, R2b, R2c, R2d, R, R′ and R″ are each independently a hydrogen atom, a halogen atom, optionally substituted C1-6 alkyl, or an optionally substituted C6-10 aryl, or two of R2a, R2b, R2c, R2d, R, R′, and R″, together with a carbon atom or a nitrogen atom to which they are attached, form a 3- to 6-membered saturated carbocyclic ring or saturated heterocyclic ring, and R3a, R3b, R3c and R5a and R5b, are as defined in the description.